MAX Chat
Company Analysis Bio-Rad Laboratories
1. Summary
Advantages
- Price (274.76 $) is less than fair price (319.41 $)
- The stock's return over the last year (-11.29%) is higher than the sector average (-16.76%).
- The company's current efficiency (ROE=-24.09%) is higher than the sector average (ROE=-73.65%)
Disadvantages
- Dividends (0%) are below the sector average (1.3%).
- Current debt level 14.68% has increased over 5 years from 5.32%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Bio-Rad Laboratories | Healthcare | Index | |
|---|---|---|---|
| 7 days | 8.7% | -8.2% | -1.2% |
| 90 days | 24.6% | -11% | 8.8% |
| 1 year | -11.3% | -16.8% | 14.3% |
BIO vs Sector: Bio-Rad Laboratories has outperformed the "Healthcare" sector by 5.47% over the past year.
BIO vs Market: Bio-Rad Laboratories has significantly underperformed the market by -25.62% over the past year.
Stable price: BIO is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: BIO with weekly volatility of -0.217% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (274.76 $) is lower than the fair price (319.41 $).
Price not significantly lower than the fair price: The current price (274.76 $) is slightly lower than the fair price by 16.3%.
4.2. P/E
P/E vs Sector: The company's P/E (-4.39) is lower than that of the sector as a whole (29.26).
P/E vs Market: The company's P/E (-4.39) is lower than that of the market as a whole (52.32).
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.4) is lower than that of the sector as a whole (10.48).
P/BV vs Market: The company's P/BV (1.4) is lower than that of the market as a whole (18.5).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (3.59) is lower than that of the sector as a whole (3.99).
P/S vs Market: The company's P/S indicator (3.59) is lower than that of the market as a whole (27.95).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-4.71) is lower than that of the sector as a whole (18.36).
EV/Ebitda vs Market: The company's EV/Ebitda (-4.71) is lower than that of the market as a whole (37.43).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -29.69% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-29.69%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-8.3%).
5.4. ROE
ROE vs Sector: The company's ROE (-24.09%) is higher than that of the sector as a whole (-73.65%).
ROE vs Market: The company's ROE (-24.09%) is lower than that of the market as a whole (36.05%).
5.5. ROA
ROA vs Sector: The company's ROA (-17.03%) is lower than that of the sector as a whole (6.71%).
ROA vs Market: The company's ROA (-17.03%) is lower than that of the market as a whole (11.45%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-0.87%) is lower than that of the sector as a whole (21.56%).
ROIC vs Market: The company's ROIC (-0.87%) is lower than that of the market as a whole (10.19%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.3%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
